<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127084</url>
  </required_header>
  <id_info>
    <org_study_id>20191005</org_study_id>
    <nct_id>NCT04127084</nct_id>
  </id_info>
  <brief_title>Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes</brief_title>
  <official_title>Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Hospital Xiamen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic kidney disease has become the leading cause for ESRD worldwide.Albuminuria is a&#xD;
      major risk factor for progression of diabetic nephropathy. SGLT2 inhibitors are the first&#xD;
      antiglycaemic drugs with direct renoprotection, which are thought to protect the kidneys by&#xD;
      lowering albuminuria, stimulating urinary glucose excretion ,reducing systemic blood&#xD;
      pressure, while simultaneously improving multiple other risk factors in a glucose-independent&#xD;
      manner. However, the precise mechanisms behind the renal beneficial effect of SGLT2&#xD;
      inhibitors are not entirely elucidated, although ongoing outcome trials will confirm these&#xD;
      findings. This study is to assess the impact of three months of treatment with SGLT2&#xD;
      Inhibitions on different levels of albuminuria in patients with type 2 diabetes and to&#xD;
      evaluate the effects of SGLT2 inhibition treatment on markers for podocyte damage , renal&#xD;
      fibrosis, inflammation，oxidative stress and renin-angiotensin- aldosterone system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The primary objective is to assess the impact of three months of treatment with&#xD;
      SGLT2 Inhibition on Different levels of Albuminuria in Patients With type 2 diabetes and to&#xD;
      seek the relationship of this influences to relevant risk markers in the pathology of&#xD;
      diabetic renal disease.&#xD;
&#xD;
      Design: prospective ，intervention， case-controlled , single center study. Treatment period:&#xD;
      12 weeks. Patient population: 60 patients with type 2 diabetes recruited from Zhongshan&#xD;
      Hospital Xiamen University in accordance with the study in- and exclusion criteria.&#xD;
&#xD;
      Intervention: Dapagliflozine 10 mg once daily tablet treatment or Empagliflozin10 mg once&#xD;
      daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment. Endpoints:&#xD;
      Primary outcome: evaluate the effects of SGLT2 inhibition treatment on on urinary&#xD;
      albuminuria, kidney function and eGFR .&#xD;
&#xD;
      Secondary endpoints To assess the effect of SGLT2 inhibition on markers for podocyte damage ,&#xD;
      renal fibrosis, inflammation，oxidative stress and renin-angiotensin- aldosterone system。&#xD;
      Timeframe: Recruiting planned from October 2019, inclusion over the following 12 months. Last&#xD;
      patient is expected to be completed October 2020. Data analysis completed December 2020,&#xD;
      publication autumn 2021.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urinary albuminuria</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>a clean-catch 24- hour urine sample and spot urine sample were collected to assess urinary albuminuria,which will be evaluated at week 0, and at end study week 12 (+/- 1 week)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in eGFR</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>eGFR was calculated by modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in nephrin</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To assess effect of SGLT2 inhibition intervention on glomerular podocyte injury by detecting the expression of renal nephrin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in TGF-β1</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To assess effect of SGLT2 inhibition intervention on glomerular and tubulointerstitial fibrosis by detecting the expression of TGF-β1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in IL-6</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To assess effect of SGLT2 inhibition intervention on inflammation biomarkers by detecting the levels of interleukin-6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in TNFα</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To evaluate the effects of SGLT2 inhibition treatment on inflammation, biomarkers by detecting the levels of tumor necrosis factor alpha.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of AGEs</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To evaluate the effects of SGLT2 inhibition treatment on oxidative stress index, the changes of AGEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of 8-OH-dG</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To evaluate the effects of SGLT2 inhibition treatment on oxidative stress index by detecting the levels of 8-OH-dG.&#xD;
Urinary 8-OH-dG concentrations were assayed using a competitive enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in uric acid</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To evaluate the levels of serum uric acid before and after SGLT2 inhibition treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aldosterone</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To evaluate the levels of aldosterone before and after SGLT2 inhibition treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rennin</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To evaluate the levels of rennin before and after SGLT2 inhibition treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in angiotensin</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>To evaluate the levels of angiotensin before and after SGLT2 inhibition treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>normal albuminuria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>baseline urinary albumin creatinine ratio [UACR]&lt; 30 mg/g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderately increased albuminuria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>baseline UACR 30~300 mg/g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>severely increased albuminuria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>baseline UACR&gt;300mg/g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank Comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>normal participant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 Inhibition</intervention_name>
    <description>Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment</description>
    <arm_group_label>moderately increased albuminuria</arm_group_label>
    <arm_group_label>normal albuminuria</arm_group_label>
    <arm_group_label>severely increased albuminuria</arm_group_label>
    <other_name>Dapagliflozine,Empagliflozin,Canagliflozin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients between 18 -80 years of age with a diagnosis of type 2&#xD;
             diabetes (WHO criteria).&#xD;
&#xD;
          2. HbA1c of 7-11 %&#xD;
&#xD;
          3. eGFR equal to or above 45 ml/min/1.73 m2&#xD;
&#xD;
          4. The Trial included 20 normal albuminuria (Urinary albumin creatinine ratio [UACR]&lt; 30&#xD;
             mg/g, with 20 moderately increased albuminuria UACR 30~300 mg/g, and 20 severely&#xD;
             increased albuminuria UACR&gt;30 0mg/g (in ≥2 out 3 morning spot urine collections prior&#xD;
             to enrolment ).at baseline.&#xD;
&#xD;
          5. Patients who agree to receive treatment with SGLT2 inhibitors.&#xD;
&#xD;
          6. Patients must be on current stable hemodynamic profile , without dehydration.&#xD;
&#xD;
          7. Patients must be on current stable antiglycaemic treatment with oral drugs (OAD) or&#xD;
             insulin 4 weeks before start of study drug and throughout study duration.&#xD;
&#xD;
          8. Patients must be on stable antihypertensive treatment (not include renin-angiotensin&#xD;
             system blocking treatment) 4 weeks before start of study drug and throughout study&#xD;
             duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. type 1 diabetes&#xD;
&#xD;
          2. Patients who suffer from recent acute complications including diabetic ketoacidosis&#xD;
             and hyperglycaemic hyperosmolar coma, which may be at risk for dehydration.&#xD;
&#xD;
          3. Patients with hypertension who are not on stable antihypertensive treatment&#xD;
&#xD;
          4. urinary tract or reproductive tract acute infection&#xD;
&#xD;
          5. impaired liver function, defined as aspartate aminotransferase (AST) &gt;3x upper limit&#xD;
             of normal (ULN) and/or alanine aminotransferase (ALT) &gt;3x ULN&#xD;
&#xD;
          6. History of unstable or rapidly progressing renal disease&#xD;
&#xD;
          7. impaired renal function ,eGFR: &lt;45 mL/min (calculated by MDRD formula)&#xD;
&#xD;
          8. Ongoing cancer treatment&#xD;
&#xD;
          9. Recent Cardiovascular Events in a patient:&#xD;
&#xD;
             9.1. Acute Coronary Syndrome (ACS) within 2 months prior to enrolment&#xD;
             9.2.Hospitalization for unstable angina or acute myocardial infarction within 2 months&#xD;
             prior to enrolment9. 3. Acute Stroke or TIA within two months prior to enrolment 9. 4.&#xD;
             Less than two months post coronary artery revascularization&#xD;
&#xD;
         10. Congestive heart failure defined as New York Heart Association (NYHA) class IV,&#xD;
             unstable or acute congestive heart failure..&#xD;
&#xD;
         11. Pregnant or breastfeeding patients&#xD;
&#xD;
         12. smoker.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-lin Zhao, principal</last_name>
    <role>Study Director</role>
    <affiliation>Zhongshan Hospital Xiamen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-min Chen, principal</last_name>
    <phone>8613860487599</phone>
    <email>chenxiaomin0517@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan Tian, assistant</last_name>
    <phone>8618250865805</phone>
    <email>411954353@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-lin Zhao, principle</last_name>
      <phone>8613950085931</phone>
    </contact>
    <investigator>
      <last_name>Xiao-min Chen, principle</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuan Tian, assistant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Albuminuria</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

